Skip to main content
logo
Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.775
+0.055 (3.20%)
At close: Sep 17, 2026, 4:00 PM EDT
1.780
+0.005 (0.28%)
After-hours: Sep 17, 2026, 4:10 PM EDT

Gain Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---0.060.130.13
Revenue Growth
----58.40%-0.96%-
Cost of Revenue
9.9910.0710.6511.388.247.16
Gross Profit
-9.99-10.07-10.65-11.32-8.11-7.03
Selling, General & Admin
9.318.669.7110.939.686.84
Other Operating Expenses
-----0.01-0.03
Operating Expenses
9.318.669.7110.939.686.81
Operating Income
-19.3-18.73-20.36-22.26-17.79-13.84
Interest & Investment Income
0.330.260.370.50.390.02
Currency Exchange Gain (Loss)
-0.23-0.830.12-0.43-0.1-0.07
Pretax Income
-19.2-19.3-19.87-22.19-17.5-13.89
Income Tax Expense
0.910.860.540.080.090
Net Income
-20.11-20.16-20.41-22.27-17.59-13.89
Net Income to Common
-20.11-20.16-20.41-22.27-17.59-13.89
Net Income Growth
------
Shares Outstanding (Basic)
393323131210
Shares Outstanding (Diluted)
393323131210
Shares Change
39.34%44.08%75.86%9.49%16.90%279.11%
EPS (Basic)
-0.51-0.61-0.89-1.71-1.48-1.37
EPS (Diluted)
-0.51-0.61-0.89-1.71-1.48-1.37
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-18.95-18.47-18.9-18.88-14.81-12.46
Free Cash Flow Per Share
-0.48-0.56-0.83-1.45-1.25-1.23
Operating Margin
----40336.86%-13410.18%-10332.05%
Profit Margin
----40354.33%-13262.02%-10371.70%
Free Cash Flow Margin
----34217.53%-11166.38%-9303.42%
EBITDA
-19.25-18.69-20.32-22.22-17.76-13.82
D&A For EBITDA
0.050.050.040.040.030.02
EBIT
-19.3-18.73-20.36-22.26-17.79-13.84
Revenue as Reported
---0.060.140.16
SEC Filings: 10-K · 10-Q